Building the future management of follicular lymphoma with T-cell–redirecting strategies Available to Purchase

2.

Kanas

G

,

Ge

W

,

Quek

RGW

,

Keeven

K

,

Nersesyan

K

,

Arnason

Jon E

.

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025

.

Leuk Lymphoma

.

2022

;

63

(

1

):

54

-

63

.

3.

Casulo

C

,

Byrtek

M

,

Dawson

KL

, et al.

Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study

.

J Clin Oncol

.

2015

;

33

(

23

):

2516

-

2522

.

4.

Link

BK

,

Day

BM

,

Zhou

X

, et al.

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

.

Br J Haematol

.

2019

;

184

(

4

):

660

-

663

.

5.

Batlevi

CL

,

Sha

F

,

Alperovich

A

, et al.

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

.

Blood Cancer J

.

2020

;

10

(

7

):

74

.

6.

Solal-Céligny

P

,

Lepage

E

,

Brousse

N

, et al.

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial

.

J Clin Oncol

.

1998

;

16

(

7

):

2332

-

2338

.

7.

Dave

SS

,

Wright

G

,

Tan

B

, et al.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells

.

N Engl J Med

.

2004

;

351

(

21

):

2159

-

2169

.

8.

de Jong

D

,

Koster

A

,

Hagenbeek

A

, et al.

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

.

Haematologica

.

2009

;

94

(

1

):

70

-

77

.

9.

Leonard

JP

,

Trneny

M

,

Izutsu

K

, et al.

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

.

J Clin Oncol

.

2019

;

37

(

14

):

1188

-

1199

.

10.

Morschhauser

F

,

Le Gouill

S

,

Feugier

P

, et al.

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

.

Lancet Haematol

.

2019

;

6

(

8

):

e429

-

e437

.

11.

Lansigan

F

,

Andorsky

DJ

,

Coleman

M

, et al.

P1156: magnify phase 3B study of lenalidomide + rituximab (R2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma: complete induction phase analysis

.

Hemasphere

.

2022

;

6

:

1043

-

1044

.

12.

Morschhauser

F

,

Fowler

NH

,

Feugier

P

, et al.

Rituximab plus lenalidomide in advanced untreated follicular lymphoma

.

N Engl J Med

.

2018

;

379

(

10

):

934

-

947

.

13.

Morschhauser

F

,

Nastoupil

L

,

Feugier

P

, et al.

Six-year results from RELEVANCE: lenalidomide plus rituximab

.

J Clin Oncol

.

2022

;

40

(

28

):

3239

-

3245

.

14.

Morschhauser

F

,

Tilly

H

,

Chaidos

A

, et al.

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

.

Lancet Oncol

.

2020

;

21

(

11

):

1433

-

1442

.

15.

Zinzani

PL

,

Mayer

J

,

Flowers

CR

, et al.

ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma

.

J Clin Oncol

.

2023

;

41

(

33

):

5107

-

5117

.

16.

Lee

DW

,

Santomasso

BD

,

Locke

FL

, et al.

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

.

Biol Blood Marrow Transplant

.

2019

;

25

(

4

):

625

-

638

.

17.

Santomasso

BD

,

Nastoupil

LJ

,

Adkins

S

, et al.

Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline

.

J Clin Oncol

.

2021

;

39

(

35

):

3978

-

3992

.

18.

Hayden

PJ

,

Roddie

C

,

Bader

P

, et al.

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

.

Ann Oncol

.

2022

;

33

(

3

):

259

-

275

.

19.

Cordeiro

A

,

Bezerra

ED

,

Hirayama

AV

, et al.

Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells

.

Biol Blood Marrow Transplant

.

2020

;

26

(

1

):

26

-

33

.

20.

Rejeski

K

,

Subklewe

M

,

Aljurf

M

, et al.

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

.

Blood

.

2023

;

142

(

10

):

865

-

877

.

21.

Rejeski

K

,

Wang

Y

,

Hansen

DK

, et al.

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

.

Blood Adv

.

2024

;

8

(

8

):

1857

-

1868

.

22.

Cordas Dos Santos

DM

,

Tix

T

,

Shouval

R

, et al.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

.

Nat Med

.

2024

;

30

(

9

):

2667

-

2678

.

23.

Hamilton

MP

,

Sugio

T

,

Noordenbos

T

, et al.

Risk of second tumors and T-cell lymphoma after CAR T-cell therapy

.

N Engl J Med

.

2024

;

390

(

22

):

2047

-

2060

.

24.

Tix

T

,

Alhomoud

M

,

Shouval

R

, et al.

Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

.

Clin Cancer Res

.

2024

;

30

(

20

):

4690

-

4700

.

25.

Jacobson

CA

,

Chavez

JC

,

Sehgal

AR

, et al.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

.

Lancet Oncol

.

2022

;

23

(

1

):

91

-

103

.

26.

Neelapu

SS

,

Chavez

JC

,

Sehgal

A

, et al.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

.

Blood

.

2024

;

143

(

6

):

496

-

506

.

27.

Neelapu

SS

,

Chavez

JC

,

Sehgal

AR

, et al.

Axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4868

.

28.

Fowler

NH

,

Dickinson

M

,

Dreyling

M

, et al.

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

.

Nat Med

.

2022

;

28

(

2

):

325

-

332

.

29.

Dreyling

M

,

Fowler

NH

,

Dickinson

M

, et al.

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

.

Blood

.

2024

;

143

(

17

):

1713

-

1725

.

30.

Morschhauser

F

,

Dahiya

S

,

Palomba

ML

, et al.

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

.

Nat Med

.

2024

;

30

(

8

):

2199

-

2207

.

31.

Meignan

M

,

Cottereau

AS

,

Versari

A

, et al.

Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies

.

J Clin Oncol

.

2016

;

34

(

30

):

3618

-

3626

.

32.

Schuster

SJ

,

Bishop

MR

,

Tam

CS

, et al.

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2019

;

380

(

1

):

45

-

56

.

33.

Vercellino

L

,

Di Blasi

R

,

Kanoun

S

, et al.

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

.

Blood Adv

.

2020

;

4

(

22

):

5607

-

5615

.

34.

Iacoboni

G

,

Simó

M

,

Villacampa

G

, et al.

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy

.

Ann Hematol

.

2021

;

100

(

9

):

2303

-

2310

.

35.

Iacoboni

G

,

Navarro

V

,

Martín-López

A

, et al.

Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy

.

J Clin Oncol

.

2024

;

42

(

2

):

205

-

217

.

36.

Flinn

IW

,

Jacobson

CA

,

Nastoupil

LJ

, et al.

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) [abstract]

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

TPS7579

.

37.

Randomized

A

.

Open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (FL) ClinicalTrials.gov identifier: NCT05888493

. Updated 23 October 2023. Accessed 18 September 2024. https://clinicaltrials.gov/study/NCT05888493.

38.

Jacobson

C

,

Hemmer

MT

,

Hu

Z

, et al.

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL)

.

Hematol Oncol

.

2023

;

41

(

S2

):

375

-

376

.

39.

Ysebaert

L

,

Houot

R

,

Casasnovas

O

, et al.

Real-word experience of CAR T-cells in patients with relapsed/refractory follicular lymphoma: a Descart registry analysis from the Lysa [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

296

.

40.

Pasquini

MC

,

Hu

ZH

,

Curran

K

, et al.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

.

Blood Adv

.

2020

;

4

(

21

):

5414

-

5424

.

41.

Bachy

E

,

Le Gouill

S

,

Di Blasi

R

, et al.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

.

Nat Med

.

2022

;

28

(

10

):

2145

-

2154

.

42.

Kwon

M

,

Iacoboni

G

,

Reguera

JL

, et al.

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

.

Haematologica

.

2023

;

108

(

1

):

110

-

121

.

43.

Jacobson

CA

,

Locke

FL

,

Ma

L

, et al.

Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States

.

Transplant Cell Ther

.

2022

;

28

(

9

):

581.e1

-

581.e8

.

44.

Bethge

WA

,

Martus

P

,

Schmitt

M

, et al.

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

.

Blood

.

2022

;

140

(

4

):

349

-

358

.

45.

Blanco

B

,

Domínguez-Alonso

C

,

Alvarez-Vallina

L

.

Bispecific immunomodulatory antibodies for cancer immunotherapy

.

Clin Cancer Res

.

2021

;

27

(

20

):

5457

-

5464

.

46.

Budde

LE

,

Sehn

LH

,

Matasar

M

, et al.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

.

Lancet Oncol

.

2022

;

23

(

8

):

1055

-

1065

.

47.

Schuster

SJ

,

Sehn

LH

,

Bartlett

NL

, et al.

Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

603

.

48.

Budde

LE

,

Assouline

S

,

Sehn

LH

, et al.

Durable responses with mosunetuzumab in relapsed/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I/II study

.

J Clin Oncol

.

2024

;

42

(

19

):

2250

-

2256

.

49.

Linton

KM

,

Vitolo

U

,

Jurczak

W

, et al.

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

.

Lancet Haematol

.

2024

;

11

(

8

):

e593

-

e605

.

50.

Kim

TM

,

Taszner

M

,

Novelli

S

, et al.

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

.

Ann Oncol

.

2024

;

35

(

11

):

1039

-

1047

.

51.

Morschhauser

F

,

Carlo-Stella

C

,

Dickinson

M

, et al.

Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL) [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

128

.

52.

Phase III randomized, open-label, multicenter study evaluating efficacy and safety of mosunetuzumab in combination with lenalidomide in comparison to rituximab in combination with lenalidomide with a non-randomized single arm US extension of mosunetuzumab in combination with lenalidomide in patients with follicular lymphoma after at least one line of systemic therapy. ClinicalTrials.gov identifier: NCT04712097

. Updated 26 October 2021. Accessed 18 September 2024. https://clinicaltrials.gov/study/NCT04712097.

53.

Flinn

IW

,

Budde

LE

,

Tun

AM

, et al.

Subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: initial results from the phase II Morningsun study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3029

.

54.

Falchi

L

,

Okwali

M

,

Ghione

P

, et al.

Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

604

.

55.

Lynch

RC

,

Poh

C

,

Shadman

M

, et al.

Early complete responses with mosunetuzumab monotherapy in treatment-naïve follicular and marginal zone lymphomas with only low-grade cytokine release syndrome [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4397

.

56.

Reynolds

G

,

Maclean

M

,

Cliff

ERS

, et al.

Infections in lymphoma patients treated with bispecific antibodies: a systematic review and meta-analysis

.

Blood Adv

.

2024

;

8

(

13

):

3555

-

3559

.

57.

Wang

M

,

Munoz

J

,

Goy

A

, et al.

Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study

.

J Clin Oncol

.

2022

;

41

(

3

):

555

-

567

.

58.

Wang

Y

,

Jain

P

,

Locke

FL

, et al.

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results From the US Lymphoma CAR T Consortium

.

J Clin Oncol

.

2023

;

41

(

14

):

2594

-

2606

.

59.

Rejeski

K

,

Perez

A

,

Iacoboni

G

, et al.

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

.

J Immunother Cancer

.

2022

;

10

(

5

):

e004475

.

60.

Lemoine

J

,

Bachy

E

,

Cartron

G

, et al.

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

.

Blood Adv

.

2023

;

7

(

21

):

6589

-

6598

.

61.

Ghilardi

G

,

Fraietta

JA

,

Gerson

JN

, et al.

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

.

Nat Med

.

2024

;

30

(

4

):

984

-

989

.

62.

Storgard

R

,

Rejeski

K

,

Perales

MA

,

Goldman

A

,

Shouval

R

.

T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy

.

JAMA Oncol

.

2024

;

10

(

6

):

826

-

828

.

63.

Levine

BL

,

Pasquini

MC

,

Connolly

JE

, et al.

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

.

Nat Med

.

2024

;

30

(

2

):

338

-

341

.

64.

Harrison

SJ

,

Nguyen

T

,

Rahman

M

, et al.

CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

6939

.

65.

Bosch

F

,

Kuruvilla

J

,

Vassilakopoulos

TP

, et al.

Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma

.

Clin Lymphoma Myeloma Leuk

.

2024

;

24

(

2

):

105

-

121

.

66.

Nastoupil

L J

,

Bonner

A

,

Wang

P

, et al.

Matching-adjusted indirect comparison (MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (Tx) of third line or later (3L+) relapsed or refractory (R/R) follicular lymphoma (FL) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

2338

.

67.

Crochet

G

,

Iacoboni

G

,

Couturier

A

, et al.

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

.

Blood

.

2024

;

144

(

3

):

334

-

338

.

68.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

69.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2022

;

41

(

12

):

2238

-

2247

.

70.

Iacoboni

G

,

Iraola-Truchuelo

J

,

O'Reilly

M

, et al.

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy

.

Hemasphere

.

2024

;

8

(

5

):

e62

.

71.

Schuster

SJ

,

Huw

LY

,

Bolen

CR

, et al.

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

.

Blood

.

2024

;

143

(

9

):

822

-

832

.

72.

Maurer

MJ

,

Prochazka

VK

,

Flowers

CR

, et al.

FLIPI24: an improved international prognostic model developed on early events in follicular lymphoma [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

2292

-

2295

.

73.

Casulo

C

,

Larson

MC

,

Flowers

CR

, et al.

The FLIPI24 prognostic model identifies poor outcomes in non-immunochemotherapy treated patients with follicular lymphoma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1657

.